MARKET

SQZ

SQZ

SQZ Biotechnologies Co
NYSE

Real-time Quotes | Nasdaq Last Sale

15.27
+0.03
+0.20%
After Hours: 15.27 0 0.00% 16:00 09/24 EDT
OPEN
15.17
PREV CLOSE
15.24
HIGH
15.38
LOW
14.89
VOLUME
31.80K
TURNOVER
--
52 WEEK HIGH
36.49
52 WEEK LOW
11.15
MARKET CAP
428.28M
P/E (TTM)
-6.1210
1D
5D
1M
3M
1Y
5Y
10 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie
In this article, we will take a look at 10 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie. You can skip our detailed analysis of Lee Ainslie’s history, investment strategy, and hedge fund performance, and go directly to s...
Insider Monkey · 5d ago
Illumina Ventures Closes $325 Million Fund
Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million. The latest fund is ...
Business Wire · 5d ago
BRIEF-SQZ Biotechnologies Announces First Autoimmune Disease Indication For Tolerizing Antigen Carrier (TAC) Platform
reuters.com · 09/13 11:35
SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform
WATERTOWN, Mass., September 13, 2021--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the first clinical translation of the company’s Tolerizing Antigen Carrier...
Business Wire · 09/13 10:45
SQZ Biotechnologies to Present at Upcoming Health Care Conferences
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at Citi's 16th Annual Virtual Biopharma Conference on September 10, and at the H. ...
Business Wire · 09/09 10:45
SQZ Biotechnologies Chief Medical Officer Oliver Rosen Plans to Resign in Mid September
MT Newswires · 09/02 17:26
683 Capital Management, LLC Buys Cardlytics Inc, TWC Tech Holdings II Corp, Tailwind ...
GuruFocus News · 08/24 16:38
Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 08/17 18:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SQZ. Analyze the recent business situations of SQZ Biotechnologies Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SQZ stock price target is 36.25 with a high estimate of 46.00 and a low estimate of 29.00.
EPS
Institutional Holdings
Institutions: 47
Institutional Holdings: 13.46M
% Owned: 47.97%
Shares Outstanding: 28.05M
TypeInstitutionsShares
Increased
26
3.45M
New
11
307.66K
Decreased
6
128.03K
Sold Out
9
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Amy Schulman
President/Chief Executive Officer/Founder/Director
Armon Sharei
Chief Financial Officer
Teri Loxam
Chief Human Resource Officer
David First
Chief Scientific Officer
Howard Bernstein
General Counsel
Lawrence Knopf
Other
Oliver Rosen
Other
Micah Zajic
Independent Director
Paul Bolno
Independent Director
Bernard Coulie
Independent Director
Marc Elia
Independent Director
Pushkal Garg
Independent Director
Klavs Jensen
Independent Director
Marc Schegerin
Independent Director
Sapna Srivastava
Independent Director
Patrick Vink
No Data
About SQZ
SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. It uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in highly immunogenic (HPV) plus tumors. It is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating robust (cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that has been designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.

Webull offers kinds of SQZ Biotechnologies Co stock information, including NYSE:SQZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SQZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SQZ stock methods without spending real money on the virtual paper trading platform.